Sofinnova Investments
Sofinnova Investments reported 60 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are NTRA (31.6%), GMAB (7.7%) and JAZZ (4.8%). Compared with Q2 2026, the fund opened new positions in AZN, LLY and NVS, added to GMAB, JAZZ and AXSM, trimmed IMNM, IMTX and BMY and sold out of SUPN, GILD and COGT.
Latest filing: what Sofinnova Investments did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() NTRA Natera Inc | $641M | 31.6% | 1.6M | No change | 8 of 8 | |
| 2 | ![]() GMAB Genmab A/s | $155M | 7.7% | 4.3M | +304K (+8%) | 3 of 8 | |
| 3 | ![]() JAZZ Jazz Pharmaceuticals PLC | $97.8M | 4.8% | 422K | +57K (+16%) | 8 of 8 | |
| 4 | ![]() VERA Vera Therapeutics Inc | $90.2M | 4.5% | 2.8M | No change | 8 of 8 | |
| 5 | ![]() AXSM Axsome Therapeutics Inc | $82.2M | 4.1% | 446K | +285K (+178%) | 8 of 8 | |
| 6 | ![]() SPTX Seaport Therapeutics Inc | $71.9M | 3.5% | 3.6M | No change | 2 of 8 | |
| 7 | ![]() RAPP Rapport Therapeutics Inc | $64M | 3.2% | 1.9M | No change | 8 of 8 | |
| 8 | ![]() AZN Astrazeneca PLC Ord | $61.9M | 3.0% | 383K | New position | 2 of 8 | |
| 9 | ![]() AVBP Arrivent Biopharma Inc | $51.4M | 2.5% | 1.7M | No change | 8 of 8 | |
| 10 | ![]() RYTM Rhythm Pharmaceuticals Inc | $50.9M | 2.5% | 535K | +127K (+31%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() SUPN Supernus Pharmaceuticals Inc | $48.2M | 1M |
![]() GILD Gilead Sciences Inc | $43.3M | 343K |
![]() COGT Cogent Biosciences Inc | $40.1M | 1M |
![]() ALC Alcon AG | $17.2M | 256K |
![]() INSM Insmed Inc | $16.9M | 158K |
🔒 Free account: see all 9.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() IWM Ishares TR | Put | $139M | 500K | +500,000 |
![]() QQQ Invesco Qqq TR | Put | $55.5M | 75K | +75,000 |
![]() BMY Bristol Myers Squibb Co | Call | $43.7M | 700K | +700,000 |
![]() IRON Disc Medicine Inc | Put | $13.1M | 200K | +200,000 |
![]() EWTX Edgewise Therapeutics Inc | Put | $12.2M | 300K | +300,000 |
🔒 Free account: see all 7.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Sofinnova Investments 13F FAQ
What does Sofinnova Investments own?
Sofinnova Investments reported 60 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are NTRA (31.6%), GMAB (7.7%) and JAZZ (4.8%). The table above lists every position in the filing (the top 10 without an account).
What did Sofinnova Investments buy and sell in Q3 2026?
Compared with Q2 2026: 16 new positions, 14 added to, 19 trimmed and 9 sold out. New positions include AZN, LLY and NVS. It sold all of SUPN, GILD and COGT.
When will Sofinnova Investments file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Sofinnova Investments's portfolio worth?
The Q3 2026 filing reports $2B in US stocks ($2.3B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.




























